Literature DB >> 16380113

Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'.

Andrew Gardner1, Paul E Mallet.   

Abstract

This study compared the effects of the putative cannabinoid receptor 'silent antagonist' O-2050 with the cannabinoid receptor inverse agonist SR 141716 on food and water consumption, and locomotor activity. Non-deprived male Wistar rats were habituated to the apparatus and testing procedures, then injected intraperitoneally with vehicle, O-2050 (0.03-3.0 mg/kg), or SR 141716 (3.0 mg/kg) prior to 4-h test sessions. Food consumption was significantly reduced by both drugs. Water intake and locomotor activity were significantly reduced only by O-2050. Results support the notion that cannabinoid receptor antagonists suppress feeding behaviour by blocking an endogenous cannabinoid orexigenic signal, rather than by inverse agonism at cannabinoid receptors. However, further studies are needed to confirm the status of O-2050 as a cannabinoid CB(1) receptor antagonist devoid of inverse agonist properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16380113     DOI: 10.1016/j.ejphar.2005.11.032

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  25 in total

Review 1.  The behavioral pharmacology of anorexigenic drugs in nonhuman primates: 30 years of progress.

Authors:  Richard W Foltin
Journal:  Behav Pharmacol       Date:  2012-09       Impact factor: 2.293

2.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

3.  The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.

Authors:  Kelly S Sink; Peter J McLaughlin; Jodi Anne T Wood; Cara Brown; Pusheng Fan; V Kiran Vemuri; Yan Peng; Yan Pang; Teresa Olszewska; Teresa Olzewska; Ganesh A Thakur; Alex Makriyannis; Linda A Parker; John D Salamone
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

Review 4.  Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions.

Authors:  John D Salamone; Peter J McLaughlin; Kelly Sink; Alexandros Makriyannis; Linda A Parker
Journal:  Physiol Behav       Date:  2007-04-14

5.  The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats.

Authors:  Janel Hodge; Joshua P Bow; Kimberly S Plyler; V Kiran Vemuri; Ania Wisniecki; John D Salamone; Alexandros Makriyannis; Peter J McLaughlin
Journal:  Behav Brain Res       Date:  2008-06-17       Impact factor: 3.332

6.  Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.

Authors:  Lirit N Franks; Benjamin M Ford; Nikhil R Madadi; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Eur J Pharmacol       Date:  2014-05-20       Impact factor: 4.432

7.  Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.

Authors:  Joost Wiskerke; Nicky Stoop; Dustin Schetters; Anton N M Schoffelmeer; Tommy Pattij
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

8.  The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats.

Authors:  K S Sink; K N Segovia; L E Collins; E J Markus; V K Vemuri; A Makriyannis; J D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2010-03-27       Impact factor: 3.533

9.  Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.

Authors:  K S Sink; K N Segovia; J Sink; P A Randall; L E Collins; M Correa; E J Markus; V K Vemuri; A Makriyannis; J D Salamone
Journal:  Eur Neuropsychopharmacol       Date:  2009-12-16       Impact factor: 4.600

10.  Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice.

Authors:  Xia Li; Alexander F Hoffman; Xiao-Qing Peng; Carl R Lupica; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.